Praxis Precision Medicines, Inc. PRAX Total debt
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $1.4M.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s total debt?
- Praxis Precision Medicines, Inc. (PRAX) reported total debt of $1.4M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s total debt changed year-over-year?
- Praxis Precision Medicines, Inc.'s total debt increased by 31.3% year-over-year, from $1.07M to $1.4M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s total debt?
- Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s total debt has grown at a -32.1% compound annual growth rate (CAGR), from $763K to $110K.
- What does total debt mean?
- The total amount of money the company owes to banks, bondholders, and other lenders.
- How do you interpret total debt?
- An increase in total debt suggests higher financial leverage and increased interest expense, which may be necessary for funding clinical trials but raises solvency risks. A decrease indicates deleveraging, which improves the balance sheet strength but may limit available capital for research and development.
- How does total debt compare across companies?
- For clinical-stage biopharmaceutical companies, total debt levels are typically low compared to established commercial-stage firms, as these companies often rely on equity financing or strategic partnerships to fund operations.